# Avitide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avitide

- Industry: Biotechnology
- Headquarters: Lebanon, US
- Website: www.avitide.com
- Total disclosed funding: $21M
- Latest round: Series E (Jun 21, 2017)
- Investors on record: 7

## About

Avitide, Inc. specializes in advanced affinity purification solutions for the biopharmaceutical manufacturing sector, enhancing production efficiency through proprietary technology.Avitide, Inc. was founded in 2012 in Lebanon, US, focusing on the development of purification technologies. The company has engaged in a total of 8 deals, with the most recent deal occurring on October 15, 2019. Avitide raised USD 10 mn in venture funding during this round, which marked the total amount raised to date. The company’s leadership includes co-founders Errik Anderson, Kevin Isett, and Warren Kett, while Kevin Isett serves as the CEO, bringing significant industry experience to the firm.Avitide specializes in the development and supply of affinity purification solutions tailored for the biopharmaceutical manufacturing industry. The company's core offerings include its proprietary AVIPure™ affinity resins, which are the first and only serotype-specific resins for adeno-associated viruses (AAV) that are regenerable using NaOH. These resins maintain a recovery rate of 96% even after 20 cycles with 0.5M NaOH, addressing challenges in the purification processes for a wide range of biopharmaceuticals, including next-generation biotherapeutics. Avitide's solutions facilitate efficient custom and platform applications, contributing to enhanced purity, yield, and efficiency in production, serving a global client base that impacts over 250 million potential patients across North America, Europe, and parts of Asia.Avitide generates revenue through direct business-to-business transactions in the biopharmaceutical sector, primarily from the sale and licensing of its AVIPure™ affinity resins and purification technologies. The company engages in partnerships and collaborations with biopharmaceutical manufacturers, providing commercial resin supply alongside development support. Agreements with clients often include supply contracts for ongoing production needs, ensuring quality and reliability while meeting clinical and commercial demands. Avitide’s pricing strategies reflect the specialized nature of its products and services, catering to the requirements of custom bioprocessing solutions and premium-grade affinity resins, thereby securing revenue and establishing long-term partnerships that enhance operational efficiencies.Avitide plans to leverage its recent funding of USD 10 mn, raised in October 2019, to further develop new products in affinity purification technology. The company aims to introduce these innovative solutions to enhance its product line by the end of 2021. Additionally, Avitide is targeting expansion into new international markets, particularly in Europe and Asia, with plans to establish a presence in these regions by 2023. The funding will support the development of these new offerings and facilitate market entry strategies.

## Funding rounds

- Series E, Jun 21, 2017, $12M — OrbiMed Advisors, Polaris Partners, NeoMed, Borealis Ventures, Mithril, Sands Capital Alternatives
- Series D, Sep 12, 2016 — Mithril
- Series C, Aug 6, 2015, $7.5M — OrbiMed Advisors, Polaris Partners, SV Health Investors, NeoMed, Borealis Ventures
- Series A, Mar 15, 2013, $1.4M — OrbiMed Advisors, Polaris Partners, SV Health Investors, Borealis Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series C, Series E
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series C, Series E
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series C
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series A, Series C, Series E
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series C, Series E
- Mithril (https://capitalatlas.ai/funds/mithril) — Series D, Series E
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series E